Pharvaris' Phase 3 Trial of Deucrictibant for HAE Attacks Confirms a Differentiated On-Demand Profile, Morgan Stanley Says

MT Newswires Live12-05

Pharvaris' (PHVS) phase 3 trial of deucrictibant for hereditary angioedema attacks meeting primary and secondary endpoints confirms a differentiated oral on-demand profile, Morgan Stanley said in a Wednesday note.

The company remains on track for new drug application submission to the US Food and Drug Administration in H1 2026, with the prophylactic data readout from the ongoing chapter-3 phase 3 study expected in H2 2026, according to the note.

The firm said that the prophylactic opportunity is larger than on-demand, with Pharvaris guiding to 67% of the population at present, growing to around 80% in terms of value in the prophylactic space.

The firm said it modeled a 65% probability of success for the prophylactic candidate and a 90% probability of success for the on-demand candidate.

Morgan Stanley raised the company's price target to $41 from $37, with an overweight rating.

Price: 28.16, Change: -1.21, Percent Change: -4.10

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589835185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589835185","market":"sh","top_or_hot":-1,"title":"Pharvaris' Phase 3 Trial of Deucrictibant for HAE Attacks Confirms a Differentiated On-Demand Profile, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> Pharvaris' (PHVS) phase 3 trial of deucrictibant for hereditary angioedema attacks meeting primary and secondary endpoints confirms a differentiated oral on-demand profile, Morgan Stanley said in a Wednesday note.</p><p>The company remains on track for new drug application submission to the US Food and Drug Administration in H1 2026, with the prophylactic data readout from the ongoing chapter-3 phase 3 study expected in H2 2026, according to the note.</p><p>The firm said that the prophylactic opportunity is larger than on-demand, with Pharvaris guiding to 67% of the population at present, growing to around 80% in terms of value in the prophylactic space.</p><p>The firm said it modeled a 65% probability of success for the prophylactic candidate and a 90% probability of success for the on-demand candidate.</p><p>Morgan Stanley raised the company's price target to $41 from $37, with an overweight rating.</p><p>Price: 28.16, Change: -1.21, Percent Change: -4.10</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharvaris' Phase 3 Trial of Deucrictibant for HAE Attacks Confirms a Differentiated On-Demand Profile, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharvaris' Phase 3 Trial of Deucrictibant for HAE Attacks Confirms a Differentiated On-Demand Profile, Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-05 00:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Pharvaris' (PHVS) phase 3 trial of deucrictibant for hereditary angioedema attacks meeting primary and secondary endpoints confirms a differentiated oral on-demand profile, Morgan Stanley said in a Wednesday note.</p><p>The company remains on track for new drug application submission to the US Food and Drug Administration in H1 2026, with the prophylactic data readout from the ongoing chapter-3 phase 3 study expected in H2 2026, according to the note.</p><p>The firm said that the prophylactic opportunity is larger than on-demand, with Pharvaris guiding to 67% of the population at present, growing to around 80% in terms of value in the prophylactic space.</p><p>The firm said it modeled a 65% probability of success for the prophylactic candidate and a 90% probability of success for the on-demand candidate.</p><p>Morgan Stanley raised the company's price target to $41 from $37, with an overweight rating.</p><p>Price: 28.16, Change: -1.21, Percent Change: -4.10</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2028103732.USD","symbol_name":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2589835185","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589835185","pubTimestamp":1764864034,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pharvaris'  phase 3 trial of deucrictibant for hereditary angioedema attacks meeting primary and secondary endpoints confirms a differentiated oral on-demand profile, Morgan Stanley said in a Wednesday note.The company remains on track for new drug application submission to the US Food and Drug Administration in H1 2026, with the prophylactic data readout from the ongoing chapter-3 phase 3 study expected in H2 2026, according to the note.The firm said that the prophylactic opportunity is larger than on-demand, with Pharvaris guiding to 67% of the population at present, growing to around 80% in terms of value in the prophylactic space.The firm said it modeled a 65% probability of success for the prophylactic candidate and a 90% probability of success for the on-demand candidate.Morgan Stanley raised the company's price target to $41 from $37, with an overweight rating.Price: 28.16, Change: -1.21, Percent Change: -4.10","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0971096721.USD":"富达环球金融服务 A","LU1548497426.USD":"安联环球人工智能AT Acc","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU0106831901.USD":"贝莱德世界金融基金A2","BK4585":"ETF&股票定投概念","BK4198":"医疗保健用品","LU0882574139.USD":"富达环球消费行业基金A ACC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","MS":"摩根士丹利","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","HAE":"美国血液技术","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","BK4504":"桥水持仓","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","PHVS":"Pharvaris N.V.","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4588":"碎股","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","BK4007":"制药","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0557290698.USD":"施罗德环球可持续增长基金"},"translate_title":"摩根士丹利表示，Pharvaris针对HAE攻击的deucrictibant 3期试验证实了差异化的按需模式","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HAE":1.5,"PHVS":1,"MS":0.9},"content_text":"Pharvaris' (PHVS) phase 3 trial of deucrictibant for hereditary angioedema attacks meeting primary and secondary endpoints confirms a differentiated oral on-demand profile, Morgan Stanley said in a Wednesday note.The company remains on track for new drug application submission to the US Food and Drug Administration in H1 2026, with the prophylactic data readout from the ongoing chapter-3 phase 3 study expected in H2 2026, according to the note.The firm said that the prophylactic opportunity is larger than on-demand, with Pharvaris guiding to 67% of the population at present, growing to around 80% in terms of value in the prophylactic space.The firm said it modeled a 65% probability of success for the prophylactic candidate and a 90% probability of success for the on-demand candidate.Morgan Stanley raised the company's price target to $41 from $37, with an overweight rating.Price: 28.16, Change: -1.21, Percent Change: -4.10","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589835185","isCrawlerRequest":true}